LFMD LifeMD, Inc.
FY2025 10-K
LifeMD, Inc. (LFMD) filed its fiscal year 2025 10-K annual report with the SEC on Mar 10, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: vertically integrated virtual healthcare and pharmacy platform serving 328,000 active subscribers primarily via subscription telehealth
- • New pharmacy facility opened Nov 2024 with 22,500 sq ft, 5,000 daily prescription capacity; added advanced non-sterile compounding in Sept 2025
Management Discussion & Analysis
- • Revenue $210M, up 5% YoY from $200M in 2024
- • Operating margin 18.2% vs 16.9% in prior year
Risk Factors
- • Regulatory risk: Compliance with One Big Beautiful Bill Act (OBBBA) effective Jan 1, 2025, extending telehealth HSAs pre-deductible coverage
- • Macroeconomic risk: Medicare expansion exposure to 21M Part B beneficiaries in 26 states, now 49 states coverage infrastructure in place
Financial SummaryXBRL
Revenue
$194M
Net Income
$14M
Gross Margin
85.7%
Operating Margin
-4.0%
Net Margin
7.4%
ROE
62.0%
Total Assets
$70M
EPS (Diluted)
$0.25
Operating Cash Flow
$8M
Source: XBRL data from LifeMD, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on LifeMD, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.